Kodiak Sciences (KOD) stock gains as J.P. Morgan upgrades, arguing that a recent trial readout from Roche (RHHBY) derisked the firm's eye drug KSI-101. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback